Biểu đồ giá cổ phiếu GTBP
GTBP Giá
GT Biopharma Inc
$0.32
-5.92%
$-0.02
Khi đóng cửa: May 12, 16:00:00 GMT-4
$0.33
2.29%
$0
Phiên sau giờ: May 12, 20:00:00 GMT-4
Quay lại
GT Biopharma Inc (GTBP) Giá
Thống kê chính
Giá đóng cửa trước
$0.3429
Giá mở cửa
$0.3326
Phạm vi ngày
$0.3105 - $0.3365
Phạm vi 52 tuần
$0.261 - $3.85
Khối lượng
606.2K
Khối lượng trung bình
1.0M
Tỷ suất cổ tức
--
EPS (TTM)
-10.78
Vốn hóa thị trường
$10.4M
GTBP là gì?
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The company is headquartered in San Francisco, California and currently employs 1 full-time employees. The company went IPO on 2013-10-22. The firm is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The firm also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.
